Evidence map›Paper›PMID 33648910›Full record

ArticleEuropean journal of dermatology : EJD2021

Review of the European Society for Photodynamic Therapy (Euro-PDT) Annual Congress 2020.

Colin A Morton, Rolf-Markus Szeimies, Lasse R Braathen

Open access · hybridAbstract read
In one paragraph

Article in European journal of dermatology : EJD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Daylight-PDT: everything under the sun.Biochemical Society transactions · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Colin A MortonDepartment of Dermatology, Stirling Community Hospital, Stirling, UK.
Rolf-Markus SzeimiesDepartment of Dermatology and Allergology, Klinikum Vest GmbH Academic, Teaching Hospital, Recklinghausen, Germany.
Lasse R BraathenPrivate Office, Berne, Switzerland.
Klinikum Vest · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article reviews the 2020 European Society for Photodynamic Therapy (Euro-PDT) Annual Congress. Cutting edge studies included assessment of immunohistochemical variables influencing response of basal cell carcinomas and Bowen's disease to PDT with p53, the only biomarker associated with good response in both conditions. A further study indicated that analysis of molecular markers, such as PIK3R1, could help select patients with actinic keratoses who demonstrate the best response to daylight PDT. Novel delivery protocols include artificial daylight, and laser-assisted and textile PDT. The meeting learnt of novel indications including antimicrobial PDT, as well as methods to optimise daylight PDT, including combination therapy for actinic keratoses. Adverse events were reviewed and options for painless and efficient PDT assessed, including the effect of reduced drug-light interval. A smartphone application was also evaluated which may be used to assist clinicians and patients in effective dosing and timing of daylight PDT via computational algorithms using data from earth observation satellites, to send light and ultraviolet dose information directly to patients' smart phones.

Indexed as

PhotochemotherapyCongresses as TopicEuropeHumansSkin DiseasesSocieties, Medicalactinic keratosesbiomarkersdaylightdosimetrynon-melanoma skin cancerphotodynamic therapy

Identifiers

PMID33648910
PMCPMC8120754
OpenAlexW3134223344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.